Document is current
Any future updates will be listed below
-
Authors
Al-Hilal, Taslim A.
Chrysovergi, Maria-Anna https://orcid.org/0009-0007-4139-4666
Grasberger, Paula E.
Liu, Fei https://orcid.org/0000-0002-5774-310X
Auernheimer, Vera
Zhou, Yan
Xiao, Zebin https://orcid.org/0000-0002-3311-7403
Leon-Duque, Mark Anthony https://orcid.org/0000-0002-6894-2980
Santos, Alba
Islam, Tamanna
Ligorio, Matteo
Sicard, Delphine https://orcid.org/0000-0002-1062-6205
Probst, Clemens K.
Vrbanac, Vladimir
Reddi, Tejaswini S. https://orcid.org/0000-0002-6616-9138
Vincent, Ludovic
Happe, Cassandra
Chaum, Edward https://orcid.org/0000-0003-3542-8376
Yates, Charles R.
Daneshvar, Kaveh https://orcid.org/0000-0002-7863-0489
Mullen, Allan C. https://orcid.org/0000-0002-4096-3106
Ting, David https://orcid.org/0000-0002-3261-2322
White, Eric S. https://orcid.org/0000-0003-4060-8443
Kalluri, Raghu https://orcid.org/0000-0002-2190-547X
Woo, Christina M. https://orcid.org/0000-0001-8687-9105
Puré, Ellen https://orcid.org/0000-0003-2107-3711
Goldmann, Wolfgang H. https://orcid.org/0000-0003-0738-2665
Alonso, Jose Luis
Tager, Andrew M.
Engler, Adam J. https://orcid.org/0000-0003-1642-5380
Tschumperlin, Daniel J.
Lagares, David https://orcid.org/0000-0002-7317-8796
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL147059, R01 HL157384, RO1 HL092961)
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 20 May 2025
First Online: 9 September 2025
Competing interests
: D.L. is a founder and has a financial interest in both Mediar Therapeutics and Zenon Biotech. The companies are developing treatments for organ fibrosis and cancer related to this work. D.L. has received consulting fees from Merck & Co, Scholar Rock, Ono Pharma, UCB Biopharma, Calico Life Sciences, Johnson & Johnson, Inzen Therapeutics, BioHope and PureTech Health LLC that are not related to this work. D.L. has received research support from Boehringer Ingelheim, Merck & Co, Indalo Therapeutics, Ono Pharma and Unity Biotechnology, which was not used in this work. D.J.T. is a scientific advisor and has a financial interest in Zenon Biotech. D.T. has received consulting fees from ROME Therapeutics, Foundation Medicine, Inc., NanoString Technologies, EMD Millipore Sigma and Pfizer that are not related to this work. D.T. is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, Inc., which is not related to this work. D.T. receives research support from ACD-Biotechne, PureTech Health LLC and Ribon Therapeutics, which was not used in this work. D.L.’s and D.T.’s interests were reviewed and are managed by Mass General Brigham in accordance with their conflict-of-interest policies. The other authors declare no competing interests.
